229 results about "Atherosclerosis aorta" patented technology

Provided are a strain of Lactobacillus plantarum, i.e., Lactobacillus plantarum PDG8, and compositions thereof. Also provided are methods of treating cardiovascular diseases, such as atherosclerosis, using Lactobacillus plantarum PDG8 or a composition thereof.

Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity for innate immune cells are provided.

An ultrasound imaging system for guiding a user to acquire ultrasound image data sets that can be analyzed for the presence of atherosclerosis. In one embodiment, the processor is programmed to analyze ultrasound image data for a vessel of interest and to control a user interface that suggests how an operator should move a transducer to acquire ultrasound image data with the vessel of interest in a desired location. The processor stores multiple ultrasound image data sets taken along a length of the vessel of interest to be analyzed for the presence of an atheroma.

The invention discloses an application of a small molecule compound SFII in preparation of drugs for resisting pyroptosis and GSDMD inhibitors with pyroptosis resisting activity. The small molecule compound Scutellaria flavone II (SII) extracted from Scutellaria baicalensis roots plays an important role in preparation of drugs for inhibiting pyroptosis inflammation so as to prevent or treat atherosclerosis. Experiments prove that the active pharmaceutical ingredient SFII has a definite effect on promoting atherosclerosis by virtue of Gasdermin D and GSDMD mediated macrophage pyroptosis, is convenient to obtain, can be used for preparing drugs for inhibiting GSDMD protein activity to resist pyroptosis and exerting an anti-inflammatory effect so as to prevent or treat atherosclerosis, and has a remarkable effect. The small molecule compound SFII provides a new treatment strategy for atherosclerosis, and has a wide application prospect.

The invention discloses application of lobetyolin in preparation of a medicine for treating atherosclerosis, and belongs to the field of biological medicine. The atherosclerosis comprises atherosclerosis induced by a high methionine diet. Through verification, IL-33 in aortic tissues of ApoE <- / -> mice with high methionine diet is remarkably increased, and the expression level of IL-33 in the aortic tissues of the mice is remarkably reduced compared with that of a model group after the mice are treated by lobetyolin. It is proved that lobetyolin has a positive regulation effect on treatment of atherosclerosis. Through molecular docking analysis, the binding energy between the lobetyolin and the IL-33 is-7.3 kcal / mol, which indicates that the IL-33 and the lobetyolin have good binding stability. The invention provides a new idea for clinical treatment of atherosclerosis.

The invention discloses a scorpion antiatherosclerosis polypeptide and application thereof, and belongs to the technical field of traditional Chinese medicinal material polypeptides. The anti-atherosclerosis polypeptide of the Buthus martensii Karsch is one of a peptide fragment 1, a peptide fragment 2, a peptide fragment 3, a peptide fragment 4, a peptide fragment 5, a peptide fragment 6 and a peptide fragment 7, and the amino acid sequences are respectively shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7. The anti-atherosclerosis polypeptide of the Buthus martensii Karsch is an anti-atherosclerosis polypeptide of the Buthus martensii Karsch. The anti-atherosclerosis polypeptide obtained by screening can significantly reduce oxidative damage and reduce lipid deposition, especially peptide fragment 5; a theoretical basis is provided for medicinal development of the scorpion antiatherosclerosis peptide, and a potential antiatherosclerosis mechanism of the scorpion antiatherosclerosis peptide is disclosed.

The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating atherosclerosis combined with hyperhomocysteinemia and / or hyperlipidemia. The traditional Chinese medicine composition comprises the following components: ginseng, lucid ganoderma, safflower, musk, calculus bovis, bear gall, pearl, venenum bufonis, radix aconiti carmichaeli and borneol. According to the traditional Chinese medicine composition disclosed by the invention, through reasonable compatibility of all the components, at least one of indexes such as aorta plaque area, vasomotor inner diameter difference, intima-media thickness, blood fat level, homocysteine content and the like in atherosclerosis combined with hyperhomocysteinemia and / or hyperlipidemia can be effectively improved; the symptoms of atherosclerosis combined with hyperhomocysteinemia and / or hyperlipidemia are relieved from multiple aspects, and the progress of the disease course is blocked. The traditional Chinese medicine composition is controllable in quality, convenient for standardized production, safe and reliable in prescription and free of toxic and side effects on human bodies.

The invention relates to an atherosclerosis animal model feed. The atherosclerosis animal model feed comprises the following raw materials in parts by weight: 20-30 parts of casein, 0.2-0.4 part of sulfur-containing amino acid, 15-25 parts of corn starch, 5-10 parts of maltodextrin, 10-15 parts of fructose, 4-6 parts of cellulose, 15-30 parts of a high-fat substance, 0.2-0.3 part of choline tartrate, 1-2 parts of cholesterol, 3-6 parts of a mineral premix and 0.1-0.2 part of a vitamin premix, the raw material components can be directly mixed, or part of grease is pre-emulsified by adopting vitamin D3, and then the emulsified grease is mixed with other raw materials. According to the invention, the formula components of the feed are optimized, the lard oil and the anhydrous cream are used as high-fat components, and the fructose is used as a main carbon-water source; in addition, the step of adding high-fat substances is optimized, a process of pre-emulsifying part of grease is adopted, an animal model prepared from the feed is closer to the occurrence and development process of human atherosclerosis in the aspects of heredity, lipid metabolism and the like, and the animal model is more suitable for screening drugs for treating atherosclerosis.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis, and chronic obstructive pulmonary disorder (COPD).

The invention relates to application of a CBL inhibitor in preparation of a medicine for treating atherosclerosis, the CBL inhibitor medicine is preferably NX1607, and the medicine can inhibit plaque necrosis core formation in a non-lipid-dependent mode, so that atherosclerotic plaques are stabilized, and disease progression is delayed. The invention breaks through the limitation of the traditional lipid-lowering drug, directly intervenes the key pathological link of plaque instability by regulating and controlling the apoptotic cell removal mechanism in the inflammatory microenvironment, and provides a brand new targeting strategy for atherosclerosis treatment.

The invention discloses a preparation method of macrophage targeting ASD nano particles, a prepared nano carrier and application of the nano carrier, ASD active molecules can be controllably released under the stimulation of an intracellular microenvironment (high ROS and low pH), inflammation is eliminated, meanwhile, lipid efflux is increased, and therefore effective intervention on atherosclerosis is achieved. The method comprises the following steps: (1) synthesizing a 3-acrylamido phenylboronic acid monomer B; (2) synthesizing a phenylboronic acid polymer pB; (3) synthesizing a conjugate PB-ASD of a phenylboronic acid polymer pB and akebiaquinata saponin D; (4) synthesizing a mannose modified polymer Man-PEG (Polyethylene Glycol)-DSPE (Distearoyl Sulfonate And (5) blending the Man-PEG-DSPE and the conjugate PB-ASD, and preparing the macrophage targeting ASD nano particle ASD (at) DPM NPs in an oil / water system, so as to obtain the macrophage targeting ASD nano particle ASD (at) DPM NPs.

According to the atherosclerotic plaque reversal strategy recommendation method based on AI evaluation, comprehensive analysis of multi-modal data is realized through an AI large model algorithm, and a personalized intervention scheme based on dynamic risk grading is provided for doctors, so that acute cardiovascular events are reduced, and long-term prognosis of patients is improved. A set of intelligent risk grading system is constructed by using a large model algorithm and multi-modal data, and drug and nutritional supplement recommendation is performed through a large model, so that atherosclerotic plaque reversal of a patient is realized. Clinical artery image data of a patient can be processed, and risk assessment and grading are performed through the trained AI model to generate a personalized intervention scheme. Compared with a system based on rules, the AI algorithm has higher flexibility and robustness through large-scale data training, can dynamically predict the risk level of the patient according to the multi-dimensional features of the patient and provide an accurate intervention scheme, and meets the requirements of different patients.

Disclosed in the present invention are a THR-β receptor agonist, a preparation method therefor, and a use method therefor. The present invention provides a compound represented by formula (I), and a pharmaceutically acceptable salt or stereoisomer thereof. The agonist of the present invention has better THR-β agonistic activity and selectivity and strong liver-targeting ability, and can be used in metabolic diseases (such as non-alcoholic steatohepatitis (NASH), hepatic steatosis, hyperlipidemia, and obesity), cardiovascular diseases (such as atherosclerosis), and thyroid diseases (such as hypothyroidism and thyroid cancer).

The invention relates to the technical field of cardiovascular diseases, in particular to a method for verifying an in-vivo targeted delivery function of a reagent based on an atherosclerosis model. The method comprises the following steps: acquiring lesion characteristic data of an atherosclerosis site, wherein lesion characteristics comprise a lesion position, endothelial permeability, an inflammation state and a vulnerability index; preparing targeted nano microbubbles according to the lesion characteristic data, intravenously injecting the targeted nano microbubbles into a preset atherosclerosis model body, and performing multi-modal image tracking analysis to obtain in-vivo circulation distribution data of the microbubbles. Targeted nano microbubbles are customized and designed based on plaque feature data, the targeting specificity of inflammatory components such as macrophages is remarkably improved by utilizing a double-targeting ligand modification technology, and the problem of low recognition efficiency of a traditional single targeting system is solved.

The invention discloses application of macrophage exosome molecules induced by fusobacterium nucleatum, and belongs to the technical field of molecular biology. The nucleotide sequence of the macrophage exosome molecule induced by fusobacterium nucleatum is 5 '-ACUGGCUAGGGAAAAUGAUUGGAU-3', and the macrophage exosome molecule can be applied to preparation of a preparation for inducing VSMC cells to be converted into macrophage-like phenotypes, can regulate and control the atherosclerosis process, and provides a new thought and theoretical basis for further research of exosome in the atherosclerosis progress process.

The invention discloses a traditional Chinese medicine composition for treating atherosclerosis and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of vinegar turtle shell, 5-15 parts of immature bitter orange, 5-15 parts of vinegar rhizoma sparganii, 2-10 parts of arisaema cum bile, 5-15 parts of vinegar curcuma zedoary, 20-40 parts of raw oyster, 10-20 parts of radix fici simplicissimae and 5-15 parts of semen brassicae. The weight ratio of the vinegar turtle to the raw oyster to the radix fici simplicissimae is (1: 1)-(4: 1); the weight ratio of the immature bitter orange to the arisaema cum bile to the semen brassicae is (5: 1)-(4: 5). Compared with the prior art, the pharmaceutical composition has a better treatment effect on atherosclerosis, can effectively reduce the drug administration dosage, and has the advantages of low cost and better safety.

The invention discloses a drug-loaded nano carbon dot for treating atherosclerosis and a preparation method of the drug-loaded nano carbon dot, and belongs to the technical field of biological medicines. Malic acid, vitamin B1 and histamine phosphate are used as precursors, a one-step hydrothermal method is adopted to synthesize nitrogen-sulfur-phosphorus co-doped nano carbon dots NSP-CDs, a monascus extract and serotonin are loaded on the surfaces of the carbon dots through electrostatic adsorption, and the nano drug which is simple in structure and small in size and has a targeted therapy effect is prepared. The nano-drug has low cytotoxicity and good in-vivo biological safety, and can obviously reduce total cholesterol, triglyceride, low-density lipoprotein cholesterol and Hamp of a sick mouse; the results of E staining and oil red O staining show that the plaque condition of the atherosclerosis model mouse after treatment is obviously improved. The monascus extract loaded nano-drug provided by the invention can be used for treating atherosclerosis diseases, and is expected to become a novel drug for preventing and treating atherosclerosis.

An animal aortic plaque magnetic resonance imaging method and system based on a cardiac saturation band, relating to the technical field of magnetic resonance angiography. By means of a magnetic resonance scanner, a scout image of an animal is first acquired to determine a plaque imaging area and the position of a cardiac saturation band; once the cardiac saturation band has been located, respiratory gating is started to trigger collection of data, and by incorporating various magnetic resonance imaging techniques, an animal aortic plaque magnetic resonance imaging result is obtained. A high-resolution and high-contrast animal aortic plaque image can be rapidly acquired, reducing image artifacts. The present invention is suitable for basic and translational research on atherosclerosis model animals, can achieve non-invasive vascular wall structure imaging and composition analysis without applying a contrast agent, and can also implement in-vivo tracking of a new contrast agent and a drug.

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

Provided are a Lactobacillus plantarum strain, Lactobacillus plantarum PDG8, and a composition thereof. Also provided are methods using Lactobacillus plantarum PDG8 or a composition thereof for treating a cardiovascular disease such as atherosclerosis.

Triphenylphosphonium hydroxytyrosol TPP-HT, its synthesis method and application in the preparation of drugs for improving aortic endothelial cell function. TPP-HT can significantly increase the reduction of human aortic endothelial cell activity caused by saturated fatty acids, inhibit the inflammatory response and oxidative stress caused by saturated fatty acids, and at the same time increase the synthesis of ATP in vascular endothelial cells and the expression of mitochondrial complex II. By anti-inflammatory and protecting mitochondrial function, it can prevent the occurrence and development of atherosclerosis. Therefore, TPP-HT has good application prospects in preventing cardiovascular diseases such as atherosclerosis caused by high-fat-induced endothelial damage, opening up a new medical approach for preventing a series of problems of cardiovascular diseases such as atherosclerosis caused by endothelial damage due to unbalanced dietary structure, and providing a new basis for the development of new drugs.

The present invention discloses the use of dibenzo[b,f]oxepin ring compounds or pharmaceutical salts thereof shown in formula II in the preparation of drugs for upregulating KLF2 expression. The present invention also discloses the use of dibenzo[b,f]oxepin ring compounds or pharmaceutical salts thereof shown in formula II in the preparation of drugs for treating cardiovascular diseases or anti-inflammatory drugs. The inventors used the KLF2 screening model to evaluate its cardiovascular activity: using KLF2‑COS7 cells as experimental subjects, it was first discovered that dibenzo[b,f]oxepin ring compounds or pharmaceutical salts thereof have the activity of significantly upregulating the expression of target KLF2 related to atherosclerosis, anti-inflammation, etc., and have good application prospects in the treatment of atherosclerosis-related diseases. The present invention also discloses a method for preparing the dibenzo[b,f]oxepin ring compounds. #imgabs0#

The invention discloses application of MAT2A as an anti-inflammatory target spot in treatment of atherosclerosis. Research finds that in carotid plaque of a symptomatic atherosclerotic patient and aortic sinus lesions of an ApoE- / -mouse with advanced atherosclerotic plaque, the accumulation of methionine adenosine transferase 2A (MAT2A) in CD68 + macrophages is increased, an MAT2A inhibitor FIDAS-5 can play an inhibition role by combining with an MAT2A active site, and the use of the MAT2A inhibitor FIDAS-5 can be used for inhibiting the aortic sinus lesions of the ApoE- / -mouse with advanced atherosclerotic plaque. Further, inflammatory response of atherosclerosis patients is relieved, and the process of atherosclerosis is delayed The invention provides a new therapeutic target and technical means for the treatment of atherosclerosis.

A method for promoting the proliferation of anti-inflammatory macrophages and improving their anti-inflammatory effects belongs to the field of regenerative technology. In order to promote the proliferation of anti-inflammatory macrophages and enhance their anti-inflammatory effects, the present invention combines sonosensitizers and low-frequency, low-intensity ultrasound to intervene in anti-inflammatory macrophages and atherosclerosis model mice. In vitro and in vivo experiments confirm that sonosensitizers combined with low-frequency, low-intensity ultrasound can promote the proliferation of anti-inflammatory macrophages, thereby achieving the accumulation of the number of anti-inflammatory macrophages. At the same time, it can also regulate the expression levels of various pro-inflammatory / anti-inflammatory factors of anti-inflammatory macrophages, which helps to subside inflammation.

The invention belongs to the technical field of Uighur medicine composition preparation, and particularly relates to a Uighur medicine composition, a preparation method thereof and application of the Uighur medicine composition in preparation of a medicine for treating prostatitis. Based on the Uighur medicine theory, the Uighur medicine composition is prepared from fennel root bark, capparis spinosa root bark, semen cuscutae, chicory seeds, cucumber seeds, muskmelon seeds, anchusa, dracocephalum moldavica, aniseed, fennel and pogonatherum crinitum in parts by weight, has an obvious improvement effect on prostatitis, and particularly can improve pathological damage of chronic abacterial prostatitis; and the levels of various inflammatory factors including PEG2, TL-1beta, TL-6 and TNF-alpha in serum are reduced. Meanwhile, the Uighur medicine composition can be processed into particles, tablets, powder, capsules and other dosage forms, and compared with other existing Uighur medicines for reducing blood fat and treating cardiovascular and cerebrovascular diseases and atherosclerosis, the Uighur medicine composition has the advantages of being stable in dosage form, convenient to carry and take and the like.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an active oxygen responsive nano composition and a preparation method thereof. The nano composition is prepared from dilinoleoyl phosphatidyl ethanolamine (DOPE), distearoyl phosphatidyl ethanolamine-ketal thiol-polyethylene glycol (DSPE-TK-PEG), cholesterol, rhein and cerium oxide (CeO2), and is characterized in that the nano composition is prepared from dilinoleoyl phosphatidyl ethanolamine, distearoyl phosphatidyl ethanolamine-ketal thiol-polyethylene glycol (DSPE-TK-PEG), compared with the prior art, the nano composition disclosed by the invention is uniform in particle size, simple in preparation process and high in drug loading capacity, an insoluble drug rhein and an insoluble inorganic substance cerium oxide can be loaded at the same time, and targeted and positioned release of rhein and CeO2 is realized through active oxygen response; the method is a potential new strategy for treating inflammation-based atherosclerosis.

The present invention relates to pharmaceutical composition(s) comprising particles comprising one or more compounds which are inhibitors of microsomal triglyceride transfer protein and / or apolipoprotein B (Apo B) secretion, wherein at least 50% of the particles are characterized by a volume particle fraction less than 10 μm, more preferably less than 5 μm, more preferably less than 2.5 μm. The pharmaceutical composition can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.

The invention discloses a traditional Chinese medicine composition for preventing and treating atherosclerosis and plaque formation and application thereof. The traditional Chinese medicine composition comprises the following traditional Chinese medicine components in parts by weight: 10-15 parts of peach kernel, 7-12 parts of safflower, 12-18 parts of angelica sinensis, 15-25 parts of radix rehmanniae, 12-18 parts of ligusticum wallichii, 10-15 parts of radix paeoniae rubra, 12-18 parts of radix cyathulae, 12-18 parts of platycodon grandiflorum, 12-18 parts of radix bupleuri, 10-15 parts of bran-fried fructus aurantii, 4-8 parts of honey-fried licorice root, 10-15 parts of ginseng, 8-12 parts of poria cocos, 4-8 parts of rhizoma zingiberis, 10-15 parts of rhizoma cyperi, 12-18 parts of radix curcumae, 10-15 parts of cortex albiziae, 12-18 parts of rhizoma pinelliae preparata, 12-18 parts of exocarpium citri grandis, 20-30 parts of 25 parts of allium macrostemon, 25-35 parts of corn stigma, 15-25 parts of plantain herb and 25-35 parts of oyster; based on the theory of traditional Chinese medicine, all traditional Chinese medicine raw materials are screened, and through the combined action of all the raw materials, the traditional Chinese medicine composition has a remarkable curative effect on atherosclerosis and takes effect quickly.

The invention discloses a medicinal moxa composition for preventing and treating atherosclerosis and suppurative bacterial infection co-disease. The medicinal moxa composition comprises coptis chinensis, radix rehmanniae, polygala tenuifolia, juncus effuses and moxa. The medicinal folium artemisiae argyi composition disclosed by the invention can be used for effectively preventing and treating atherosclerosis and skin suppurative bacterial infection co-diseases through a multi-target synergistic effect. The medicinal moxa composition has the core effects of clearing away heart-fire, inducing diuresis for treating stranguria and promoting blood circulation to remove meridian obstruction, and forms a complete treatment system which uses cold and warm as well as treats both symptoms and root causes by purging fire for removing toxin through coptis chinensis, clearing heat and cooling blood through radix rehmanniae, soothing nerves and promoting intelligence through polygala, inducing diuresis and conducting heat downward movement through juncus effuses and combining moxa floss for warming and dredging meridians, eliminating cold to stop pain, resisting bacteria and diminishing inflammation. By inhibiting inflammatory factors, regulating epithelial cell proliferation and reaction to oxidative stress, regulating fluid shear force, atherosclerosis and Kaposi sarcoma-related herpesvirus infection-related pathways and other mechanisms, the medicinal folium artemisiae argyi composition realizes synergistic prevention and treatment of atherosclerosis and skin infection, and provides a basis for co-disease treatment.